🟠 Moderate Evidence
In 2006, researchers at a Greek medical centre administered creatine supplementation to 39 children with severe traumatic brain injuries, including infants as young as 1 year old, at doses reaching 28 grams daily—approximately five times the amount used by adult athletes. Despite parental and regulatory concerns about safety in the pediatric population, the study reported no clinically significant adverse events and documented improvements in cognitive and functional recovery outcomes compared to control groups, according to Sakellaris and colleagues, published in the Journal of Trauma.
Key takeaways
- Multiple pediatric clinical trials across 15+ years show creatine is well-tolerated in children with no safety signals, even at high doses
- A 2025 position statement by the International Society of Sports Nutrition concludes that legislative restrictions on creatine for minors lack scientific support
- Evidence demonstrates therapeutic benefit in pediatric neurological conditions including traumatic brain injury, muscular dystrophy, and metabolic disorders
Study at a Glance
| Source | Journal of Trauma |
| Study type | Randomized controlled trial |
| Sample size | N = 39 children (treatment group) |
| Population | Children aged 1–14 years with severe traumatic brain injury |
| Country | Greece |
| Duration | 6 months supplementation |
Pediatric Creatine Trials: Safety and Efficacy Timeline
Chronological overview of controlled trials in children, 2004–2025, showing study type and outcomes
Source: Sakellaris et al. (2006), Tarnopolsky et al. (2004), Kreider et al. (2025) | Georgian Medical Journal News
A Pattern of Safety Across Multiple Pediatric Conditions
The 2006 Greek trial was not an isolated case. Two years earlier, Tarnopolsky and colleagues published a controlled trial in Neurology administering creatine to 30 boys with Duchenne muscular dystrophy for 4 months, demonstrating tolerability and functional benefit. Additional pediatric studies followed, examining creatine efficacy in children undergoing chemotherapy for leukaemia (Bourgeois) and in those with inborn errors of creatine metabolism (Banerjee), with consistent findings: well-tolerated, clinically meaningful improvements, and absence of safety signals.
This consistent safety profile across diverse pediatric populations and dosing regimens—spanning ages 1 to 18 years—contrasts sharply with regulatory apprehension and public perception. The evidence from controlled trials does not align with the fear that has prompted legislation in some countries restricting creatine sales to minors.
2025 Position Statement Challenges Regulatory Restrictions
In recognition of the accumulating evidence, Kreider and colleagues published a comprehensive position statement in Frontiers in Nutrition in 2025, endorsed by the International Society of Sports Nutrition, explicitly concluding that legislative prohibitions on creatine supplementation in minors are not grounded in scientific evidence. The statement emphasises that the safety database for pediatric creatine use—particularly in clinical populations—is robust enough to challenge blanket regulatory restrictions.
The position statement represents a formal consensus among sports nutrition experts and clinical researchers, signalling a gap between policy and evidence. Health policy decisions that restrict access to evidence-supported treatments warrant periodic re-evaluation as the scientific literature evolves.
Why the Fear Persists Despite Evidence
Parental and regulatory caution around creatine in children is psychologically understandable: supplementation in minors triggers concerns about premature performance enhancement, potential long-term effects, and deviation from natural development. However, this precautionary stance has not been validated by clinical trial data. The mechanism of creatine—enhancing phosphocreatine availability in the brain and muscles, thereby improving energy metabolism during recovery—is physiologically sound, and paediatric populations possess the same enzymatic machinery as adults.
The absence of adverse events in trials involving high-dose, long-duration supplementation in vulnerable populations (infants with brain injury, children with muscular dystrophy and active malignancy) suggests that concern about safety in healthy children is disproportionate to actual risk. Clinical evidence supports the view that creatine’s benefit-to-risk profile in paediatric neurological conditions warrants consideration as an adjunct to standard care.
No clinically significant adverse events were reported in 39 children receiving creatine at 28 grams daily for 6 months, with documented improvements in cognitive and functional recovery compared to controls.
— Sakellaris and colleagues, Journal of Trauma (2006)
What this means
Frequently asked questions
Has creatine been tested in infants and very young children?
Yes. The 2006 trial by Sakellaris and colleagues enrolled children as young as 1 year old at doses up to 28 grams daily for 6 months, with no clinically significant adverse events reported. This represents one of the highest-dose, longest-duration paediatric trials in the literature.
What conditions have been studied, and did creatine show benefit?
Creatine has been evaluated in paediatric traumatic brain injury (Sakellaris, 2006), Duchenne muscular dystrophy (Tarnopolsky, 2004), leukaemia patients undergoing chemotherapy (Bourgeois), and inborn errors of creatine metabolism (Banerjee). In each case, the supplement was well-tolerated; clinical benefit was documented in neurological and functional recovery endpoints.
If creatine is safe in children, why do some countries restrict its sale to minors?
Regulatory restrictions reflect a precautionary approach rooted in perceived risks about performance enhancement and long-term effects, rather than evidence of harm. The 2025 International Society of Sports Nutrition position statement concludes that such restrictions lack scientific foundation. Policy decisions typically lag behind evolving evidence and may reflect historical caution rather than current trial data.
As paediatric neurology and sports medicine continue to evaluate creatine’s role in both clinical and athletic contexts, the evidence base will remain the anchor for policy. The current dataset—spanning over 20 years of controlled trials—establishes a compelling safety precedent that warrants reconsideration of blanket regulatory restrictions. Future research should focus on optimising dosing regimens and identifying paediatric populations most likely to benefit from supplementation.
Source: Sakellaris et al., Journal of Trauma (2006); Tarnopolsky et al., Neurology (2004); Kreider et al., Frontiers in Nutrition (2025)
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
